News

PCa18: Dilemmas in managing metastatic prostate cancer

The optimal management for prostate cancer patients with systemic, progressive disease was discussed in one of the breakout sessions, with A. Merseburger (DE) and P. Cornford (GB) examining various issues in treating hormone-naïve metastatic cancer patients and some of...

PCa18: Keeping up with fast-changing therapeutic strategies

Day 2 of the 2nd EAU Update on Prostate Cancer (PCa18) has further expanded its discussion of key topics that impact on the diagnosis and clinical management of malignant prostate disease. Participants are challenged with new approaches, insights on...

PCa18: Using bone-protective agents in advanced disease

The issue of skeletal-related events (SREs) and the timing and use of bone-protective agents were among the topics discussed in the second-day plenary session at the 2nd EAU Update on Prostate Cancer (PCa18) which is on its second and...

PCa18: Case discussions on active surveillance- an evolving topic

The afternoon breakout Case Discussions which provided PCa18 participants the opportunity to closely look into the details of prostate cancer (PCa) management dilemmas covered the still-evolving issue of active surveillance, its importance and significance particularly with regards elderly patients...

PCa18: Participants look for practical and key insights

The 2nd EAU Update on Prostate Cancer (PCa18), which opened today in Milan, has attracted participants from across Europe and beyond, and their background is as diverse as their goals in attending the two-day update meeting. Dr. Lukaz Iwanicki,...
wirth_PCa18

PCa18: Experts tackle diagnostic pitfalls in PCa management

Diagnostic issues in prostate cancer (PCa) management remain a challenging area with topics such as screening, using the right imaging tools and the role of genomics, among others, all having a significant impact on current clinical practice. With more...

PCa18: Systemic vs. targeted PCa biopsies- Choosing the right tool

Detecting high-risk prostate cancer remains a tough challenge for clinicians, but with advances in imaging and the recent results of large multi-centre studies on prostate cancer detection physicians are now better equipped to identify aggressive disease and an optimal...

PCa17: Treatment of oligometastatic prostate cancer

In men with oligometastatic prostate cancer, radical prostatectomy (RP) is linked to higher survival rates compared with other therapies, and patients also benefit from less palliative treatment.  “Local therapy (radical prostatectomy and radiation therapy) seem safe and reduce the...

PCa17: Future perspectives in prostate cancer therapies

There are a number of promising biomarkers at different molecular levels but independent and prospective validation is needed if the medical community and cancer patients are to benefit from these research outcomes. “We can expect several developments in the...